Research tools
Colonoscopy articles covering diagnosis, disease monitoring, cancer surveillance, mucosal healing, and IBD research. Research context emphasizes studies, trials, biomarkers, mechanisms, and emerging IBD science.
Page 1 of 2 · 71 articles
An oral biologic study could offer a new treatment approach for people with moderate–severe ulcerative colitis; the trial is evaluating safety and multiple measures of disease activity including endoscopy and histology.
The study focuses on children newly diagnosed with Crohn's disease who start anti-TNF treatment and aims to identify biological and clinical markers tied to complete intestinal healing after one year; results could help...
This mid-stage trial suggests a dual-targeting combo may improve endoscopic remission rates in Crohn’s disease compared with IL-23 inhibition alone, which could influence future treatment options and company strategies...
The study links lower vitamin D and higher TNF‑alpha with greater UC severity and with each other, suggesting these measurable biomarkers may reflect inflammation in ulcerative colitis.
The study explores whether people with UC in deep histologic remission can reduce or stop maintenance medications without losing remission — a question many patients and clinicians face because of medication costs, side...
Mid-stage data suggest a dual-targeting approach may improve endoscopic remission for people with moderate–severe Crohn's disease, including many who previously failed advanced therapies. If confirmed in larger trials,...
The trial tests a naturally derived oral supplement (WPMDE2) in patients with ulcerative colitis, measuring symptoms, inflammatory markers, and quality of life—outcomes that matter to people living with IBD. Early-phase...
Predicting early need for infliximab could help identify children with Crohn’s disease who may benefit from earlier biologic therapy instead of prolonged conventional treatment. A reliable prediction tool may shorten...
Earlier identification of people likely to develop IBD could shorten diagnostic delays that are linked to worse outcomes, and an automated EHR model might help target who should get earlier evaluation.
Crohn's is becoming more common among younger Americans and long-term uncontrolled inflammation raises colorectal cancer risk. Understanding possible lifestyle and medical factors can help patients and clinicians focus...
Early, easily available blood markers that predict mucosal healing could help clinicians decide sooner whether a new or intensified therapy is working, potentially reducing prolonged ineffective treatment and guiding...
This trial examines whether a blueberry-rich supplement can change inflammation, the microbiome, and intestinal barrier function in people with chronic colitis — topics many with IBD care about because diet and the...
Understanding why some IBD ulcers fail to heal could help researchers develop better treatments or biomarkers to predict healing, which matters because mucosal healing reduces hospitalizations, surgeries, and cancer...
Understanding how individual diet and microbiome patterns relate to disease activity could help create personalized dietary approaches for children with Crohn's disease and improve monitoring using home fecal...
AI-assisted detection tools and disease-specific optical classifications could improve lesion detection and real-time characterization during UC surveillance, potentially affecting surveillance accuracy and...
If you have UC, bowel urgency may indicate active inflammation more reliably than some other symptoms. Recognizing urgency could help prompt timely objective testing and treatment decisions.
Automated, validated grading of UC on colonoscopy images could reduce variability between endoscopists and help standardize severity assessment that influences treatment planning.
A reproducible animal model of perianal fistulizing Crohn’s disease could help researchers study how fistulas form and persist and provide a test platform for new therapies before human trials.
A new oral investigational drug (TP317) is entering a Phase 1b study in adults with active UC to assess safety and pharmacokinetics, which may be relevant to patients seeking information about emerging therapies.
This Phase 2 trial is testing a new oral drug (ATH-063) for adults with moderately to severely active ulcerative colitis who have not responded to prior biologic or advanced therapies, a group that often needs additional...
Automated analysis of full-length endoscopy videos could standardise assessment of UC activity, identify spatial patterns of inflammation, and better estimate histological healing—information that may influence treatment...
Researchers are testing whether blocking three inflammation pathways at once can reduce tissue inflammation more than single drugs. If ex vivo results show stronger effects, it could guide development of multi-target...
This trial tests a novel, tissue-derived cell therapy applied directly to intestinal ulcers — an approach that could lead to new local healing treatments for people with Crohn’s disease if proven safe and effective.
Researchers are studying how proteins from both the host and microbes in the gut relate to Crohn’s disease features. Findings could point to new noninvasive biomarkers or therapeutic strategies to correct dysbiosis,...
This trial tests whether oral vancomycin can help children with atypical ulcerative colitis or PSC-associated colitis and whether changes in gut bacteria or metabolites explain response. If effective and safe, it could...
The study connects a bothersome UC symptom (bowel urgency) to intestinal ultrasound signs of transmural inflammation, suggesting ultrasound might help explain and track symptom-related inflammation without relying solely...
People with stricturing Crohn’s disease currently lack effective medical treatments to prevent or reverse intestinal fibrosis; this trial explores a probiotic approach (and trehalose) aimed at stimulating autophagy, a...
People with UC have lower baseline gut microbial diversity and slower recovery after PEG bowel preparation; improving recovery of beneficial microbes could matter for symptom stability and gut health. This study suggests...
This trial tests a novel cell-derived extracellular vesicle therapy (DB-3Q) for people with Crohn’s disease who have not responded to standard advanced therapies. It may offer a different biologic approach if proven safe...
People with IBD who don’t respond well to ustekinumab may need alternative options. This study will track how patients fare after switching to guselkumab in routine clinical care and report rates of deep remission at one...
Non-invasive, inexpensive blood-derived ratios could offer easier, more frequent assessment of IBD activity than repeat endoscopy. This study evaluates several such ratios (CAR, PAR, NLR, FAR, Hb/CRP) against clinical...
Researchers are exploring ways to prioritize who needs colonoscopy sooner; adding TCM features to prediction models might change triage performance. Patients and clinicians interested in pre-endoscopic risk tools or...
This trial tests whether an oral S1P modulator (etrasimod) is more effective than standard mesalazine for inducing remission in adults with active UC — a question that could affect initial treatment choices in China.
The study will test whether routine point‑of‑care intestinal ultrasound changes clinical decisions compared with standard monitoring, which could make monitoring less invasive and more responsive if effective.
Standardized intestinal ultrasound scoring could help non-invasively monitor Crohn’s disease activity and reduce reliance on colonoscopy for some assessments. A high-sensitivity IUS score may be useful to rule out...
AI tools could make objective disease assessment faster and more consistent, help detect inflammation beyond what symptoms suggest, and ultimately support more personalized treatment choices for people with Crohn’s...
The study suggests a probiotic strain (Lactobacillus plantarum) reduced inflammation and prolonged remission in multiple mouse models of Crohn’s-like disease, indicating microbiome-based approaches might be promising to...
The trial tests two low-cost adjuncts — a Lactobacillus probiotic and a multi–trace-element supplement — added to biologic-based standard care to see if they help maintain remission in ulcerative colitis. If effective,...
This trial tests a new oral drug, AC-101, for moderate-to-severe ulcerative colitis and may expand future treatment options if it proves effective and safe. The study targets patients who have failed or could not...
People with IBD who have no or few symptoms but still have moderate–severe inflammation on endoscopy face uncertainty about whether to switch therapies to aim for endoscopic remission.
Preneoplastic (adenomatous and serrated) polyps can be precursors to colorectal cancer, so knowing how common they are and what raises risk may affect surveillance planning for people with ulcerative colitis.
Better automated segmentation of inflammatory lesions could make colonoscopy assessments more objective and consistent, which matters for monitoring IBD activity and for clinical trials that rely on endoscopic endpoints.
Phase 1 platform studies like this one test safety and tolerability of new treatments for moderate-to-severe ulcerative colitis before larger trials. Findings from such early studies determine whether a drug moves...
Early-phase trials test safety and tolerability of new mechanisms; this study evaluates an anti–IL-18 antibody (aletekitug) which could represent a different therapeutic approach for people with moderate-to-severe UC if...
This study evaluated whether blood levels of LRG track endoscopic and clinical disease activity in people with suspected UC or Crohn’s disease, which could point to a noninvasive inflammation biomarker.
People with moderate-to-severe Crohn’s disease may be interested because the study explores a new, repurposed drug (vorinostat) that targets epigenetic and immune pathways and includes a plan to move responding...
This trial tests a new oral drug (Alpha-0261) for moderate-to-severe ulcerative colitis and could matter to people who haven’t responded to standard medicines. Early-phase studies mainly assess safety but also collect...
If confirmed, an endocytoscopic appearance that corresponds to a specific miRNA and chemokine pattern could help clinicians assess mucosal inflammation during colonoscopy and prioritize biopsies or treatment decisions...
